Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 10/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10250406 | 0.94 | GRM5 (0.64) | GRM5KDM4ENPC1ALDH1A1TP53 | |
| SCHEMBL10249999 | 0.91 | GRM5 (0.77) | GRM5KDM4ENPC1ALDH1A1TP53 | |
| SCHEMBL10249995 | 0.91 | GRM5 (0.60) | GRM5 | |
| SCHEMBL10250391 | 0.90 | GRM5 (0.61) | GRM5KDM4ENPC1ALDH1A1TP53 | |
| SCHEMBL10250307 | 0.87 | GRM5 (0.81) | GRM5 | |
| SCHEMBL10250309 | 0.87 | GRM5 (0.62) | GRM5KDM4ENPC1ALDH1A1TP53 | |
| SCHEMBL10250090 | 0.87 | GRM5 (0.74) | GRM5KDM4ENPC1ALDH1A1TP53 | |
| SCHEMBL10250280 | 0.87 | GRM5 (0.67) | GRM5 | |
| SCHEMBL10250329 | 0.87 | GRM5 (0.56) | GRM5 | |
| SCHEMBL10253614 | 0.86 | GRM5 (0.74) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029190-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029190-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | GRM5 1/4885KDM4E 2855/4885NPC1 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.